PCAS S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
164,900.00
166,348.00
179,085.00
191,994.00
218,270.00
206,710
Cost of Goods Sold (COGS) incl. D&A
156,133.00
158,113.00
162,580.00
161,908.00
198,828.00
197,006
Gross Income
8,767.00
8,235.00
16,505.00
30,086.00
19,442.00
9,704
SG&A Expense
-
53,708.00
57,465.00
-
-
-
EBIT
5,365.00
4,910.00
12,424.00
10,013.00
15,463.00
5,158
Unusual Expense
1,665.00
2,040.00
1,883.00
459.00
4,784.00
1,312
Non Operating Income/Expense
35.00
254.00
2,747.00
1,672.00
428.00
6,596
Interest Expense
2,322.00
3,123.00
3,855.00
3,792.00
5,226.00
2,306
Pretax Income
1,343.00
507.00
7,705.00
4,090.00
5,885.00
5,042
Income Tax
2,194.00
2,922.00
1,075.00
2,500.00
130.00
2,687
Equity in Affiliates
106.00
51.00
-
-
-
-
Consolidated Net Income
3,431.00
2,364.00
8,780.00
6,590.00
5,755.00
2,355
Net Income
3,482.00
2,510.00
8,992.00
6,831.00
6,153.00
358
Net Income After Extraordinaries
3,482.00
2,510.00
8,992.00
6,831.00
6,153.00
358
Net Income Available to Common
3,482.00
2,510.00
8,992.00
6,831.00
6,153.00
358
EPS (Basic)
0.27
0.18
0.66
0.49
0.44
0.03
Basic Shares Outstanding
12,962.20
13,648.40
13,657.40
13,820.40
13,981.70
13,903.90
EPS (Diluted)
0.27
0.18
0.64
0.48
0.44
0.03
Diluted Shares Outstanding
12,984.20
14,028.20
14,030.10
14,166.60
14,139.70
13,903.90
EBITDA
13,786.00
13,806.00
21,628.00
19,961.00
25,935.00
16,652
Other Operating Expense
3,402.00
50,383.00
53,384.00
6,073.00
3,979.00
4,546
Non-Operating Interest Income
-
-
-
-
4.00
14
Minority Interest Expense
51.00
146.00
212.00
241.00
398.00
1,997

About PCAS

View Profile
Address
23, rue Bossuet
Longjumeau Ile-de-France 91160
France
Employees -
Website http://www.pcas.com
Updated 07/08/2019
Produits Chimiques Auxiliaires et de Synthèse SA engages in developing, manufacturing and selling of chemicals. It operates through the Pharmaceutical Synthesis and Fine Chemical sectors. The Pharmaceutical Synthesis sector manufactures active ingredients, generics, and biomaterials.